Tag Archives: transcatheter aortic valve replacement

corevalve evolutR resultados clinicos

Evolut R: Clinical Results Might Be Better than Those for First-Generation CoreValve

Evolut R: Clinical Results Might Be Better than Those for First-Generation CoreValve

Two recent articles featured in  JACC Cardiovascular Interventions  showed that short term (at 30 days) outcomes of patients treated with the next-generation self-expanding Medtronic Evolut R valves could present several advantages compared to the original CoreValve, including recapturability. Both analyses reported similar rates of all-cause mortality and stroke.   The study carried out by Dr. Jeffrey Popma as

Post-dilatación de válvulas autoexpandibles

Post-Dilation of Self-Expanding Valves: Frequency, Usefulness, and Risks

This study explores the impact of balloon post-dilation on studies conducted in the United States assessing the CoreValve self-expandable valve.   Procedural details of 3532 patients were examined to determine whether post-dilation was performed after valve implantation. Best practice guidelines recommend post-dilation to improve suboptimal outcomes, being the most frequent alternative for treating moderate or severe

Estenosis aórtica severa asintomática en añosos: ¿cuándo intervenir?

Asymptomatic Severe Aortic Stenosis in the Elderly: When to Intervene

This work studies the natural history of aortic stenosis and the optimal timing to intervene elderly patients with asymptomatic severe aortic stenosis.   This disease is increasingly misdiagnosed in the elderly population, and this goes hand in hand with enhanced therapeutic options.   Prior studies on the natural history of this disease were made on

tavi calcificación del anillo mitral

TAVR: Reasons to Consider Mitral Annular Calcification

Courtesy of Dr. Carlos Fava. Aortic valve calcification and mitral annular calcification have the same etiology and are frequently present in high-risk patients undergoing transcatheter aortic valve replacement (TAVR). The implications of mitral annular calcification for patients undergoing TAVR has not been entirely clarified yet.   The study examined 782 patients with severe aortic stenosis who underwent

predictores de reinternacion tavi

4 Readmission Predictors after Successful TAVR

Readmissions are frequent after cardiovascular procedures and they significantly increase healthcare costs. Data on readmission need within the first month after successful transcatheter aortic valve replacement (TAVR) are limited.   The registry included all TAVR patients surviving index hospitalization between January and February 2013 for readmission incidence, predictors, causes and costs within 30 days.  

Trombosis de válvulas transcatéter

Transcatheter Valve Thrombosis: Predictors, Incidence, and Events

This study sought to clarify the incidence and predictors of hypoattenuated leaflet thickening (assumed as leaflet thrombosis) imaging in transcatheter bioprosthesis.   This study involved 70 consecutive patients who underwent transcatheter aortic valve replacement with the Edwards SAPIEN-XT device and were subjected to follow-up at 6 months and 1 year through multislice computed tomography (CT), echocardiographic data, and

tavi vs cirugia partner i

TAVR vs. Surgery: Valve Performance at Five Years (PARTNER I)

The aim of this study was to evaluate the long-term performance of transcatheter aortic valve replacement (TAVR) and surgically-implanted valves through longitudinal echocardiographic follow-up of the PARTNER I trial patients.   The study included all patients receiving TAVR or undergoing surgery who had a post-implant echocardiogram at five years analyzed for peak systolic velocity, mean gradient,

Post TAVR Cognitive Function at Short Term: Better or Worse?

There is little information on the short and mid-term evolution of cognitive function after transcatheter aortic valve replacement (TAVR).   The aim of this study was to describe global changes in cognitive function and changes in specific cognitive domains one year after TAVR.   Fifty one patients undergoing TAVR, median age 80, were prospectively followed

apixaban en fibrilacion auricular tavi

Apixaban: An Alternative for Patients with Atrial Fibrillation Undergoing TAVR?

Courtesy of Dr. Carlos Fava. The prevalence of atrial fibrillation in patients undergoing transcatheter aortic valve replacement (TAVR) is high (32.9%, according to the PARTNER Trial, and 46.8%, according to the CoreValve High-Risk Study), and is associated with thromboembolic events (as in all other populations).   Apixaban has shown to benefit patients with nonvalvular atrial fibrillation,

tavi estenosis aortica severa

TAVR in Low-Flow Low-Gradient Aortic Stenosis and Severe Impairment of Systolic Function

Patients with low-flow, low-gradient severe symptomatic aortic stenosis associated with severe impairment of the left ventricular systolic function have shown acceptable outcomes after transcatheter aortic valve replacement (TAVR), according to the multicenter TOPAS-TAVI registry, which demonstrated a relatively low 30-day mortality rate.   Considering the very high risk presented by this population involved, a 30-day

Top